Southern California has had a flurry of activity—from investments by major companies to acquisitions and an IPO—over the past ...

Novartis US EVP and Chief Commercial Officer Reshema Kemps-Polanco shares how the passing of a close friend gives her work ...

In the role, Szczepan will lead scientific and AI strategy across in silico predictive modeling, translational safety analytics, and data-driven drug development solutions. Building the Regulatory ...

Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program ...

Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring ...

Novartis NOVN0.24%increase; green up pointing triangle said it agreed to buy biotech company Excellergy for up to $2 billion, adding a new approach to treat allergic diseases to its immunology ...

Novartis AG agreed to buy biotech firm Excellergy Inc. for as much as $2 billion, as it tries to strengthen its portfolio of treatments for food allergies and other immunology conditions. The ...

Novartis has penned a $2 billion deal for a biotech whose next-gen anti-immunoglobulin E (IgE) program could offer a worthy successor to Xolair. Excellergy has been snapped up by the Swiss pharma only ...

Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it collected from visitors to its consumer-facing branded drug websites. The ...

Breast cancers driven by a particular genetic signature can already be treated by a particular class of targeted therapies, but the race is on to develop next-generation medicines that improve the ...

Novartis has committed up to $3 billion—two-thirds of that upfront—toward acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics that specializes in developing PI3Kα inhibitor ...

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion to bolster its oncology pipeline. The Swiss pharma company will pay the US biotech ...